HER2-positive metastatic breast cancer
Interviews and expert commentary tagged “HER2-positive metastatic breast cancer” — the latest oncology research and clinical practice from the Audio Journal of Oncology.
Audio Journal of Oncology
Rebecca Dent MD: First-Line T-DXd Combination Adds More Than a Year of Progression Free Survival for Patients with Advanced HER2 Positive Breast Cancer
Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+
25 July 2025
0:00
Audio Journal of Oncology
The TH3RESA study: TDM-1 doubles progression free survival in HER-2 positive refractory metastatic breast cancer.
AMSTERDAM—Women with HER-2 positive metastatic breast cancer had significantly improved time to progression with fewer side effects after treatment with the antibody-drug conjugate T-DM1 compared to c
19 November 2013
0:00